Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Change in Receivables (2022 - 2025)

Historic Change in Receivables for Arcutis Biotherapeutics (ARQT) over the last 4 years, with Q3 2025 value amounting to $8.4 million.

  • Arcutis Biotherapeutics' Change in Receivables fell 4925.04% to $8.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.2 million, marking a year-over-year increase of 4213.5%. This contributed to the annual value of $47.3 million for FY2024, which is 17240.19% up from last year.
  • Per Arcutis Biotherapeutics' latest filing, its Change in Receivables stood at $8.4 million for Q3 2025, which was down 4925.04% from $21.3 million recorded in Q2 2025.
  • Arcutis Biotherapeutics' Change in Receivables' 5-year high stood at $21.3 million during Q2 2025, with a 5-year trough of $2.2 million in Q3 2023.
  • Over the past 4 years, Arcutis Biotherapeutics' median Change in Receivables value was $6.4 million (recorded in 2023), while the average stood at $8.9 million.
  • Its Change in Receivables has fluctuated over the past 5 years, first surged by 65153.85% in 2024, then tumbled by 4925.04% in 2025.
  • Over the past 4 years, Arcutis Biotherapeutics' Change in Receivables (Quarter) stood at $6.0 million in 2022, then grew by 6.02% to $6.4 million in 2023, then skyrocketed by 121.06% to $14.1 million in 2024, then crashed by 40.33% to $8.4 million in 2025.
  • Its Change in Receivables stands at $8.4 million for Q3 2025, versus $21.3 million for Q2 2025 and $12.3 million for Q1 2025.